About Contineum Therapeutics, Inc. Class A Common Stock
https://www.contineum-tx.comContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
CEO
Carmine N. Stengone MBA, MS
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 24
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:2.12M
Value:$24.95M
JOHNSON & JOHNSON
Shares:1.98M
Value:$23.28M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:1.72M
Value:$20.23M
Summary
Showing Top 3 of 65
About Contineum Therapeutics, Inc. Class A Common Stock
https://www.contineum-tx.comContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $14.85M ▼ | $-12.79M ▲ | 0% | $-0.45 ▲ | $-12.71M ▲ |
| Q2-2025 | $0 | $17.82M ▼ | $-16.04M ▼ | 0% | $-0.62 | $-15.96M ▲ |
| Q1-2025 | $0 | $18.11M ▲ | $-15.99M ▼ | 0% | $-0.62 ▲ | $-18.03M ▼ |
| Q4-2024 | $0 | $-84.74M ▼ | $-14.56M ▼ | 0% | $-0.65 ▼ | $-14.49M ▼ |
| Q3-2024 | $0 | $12.97M | $-10.27M | 0% | $-0.4 | $-10.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $182.41M ▲ | $190.85M ▲ | $10.38M ▼ | $180.47M ▲ |
| Q2-2025 | $175.48M ▼ | $182.89M ▼ | $11.5M ▼ | $171.39M ▼ |
| Q1-2025 | $190.71M ▼ | $198.26M ▼ | $13.5M ▼ | $184.77M ▼ |
| Q4-2024 | $204.76M ▼ | $212.85M ▼ | $14.78M ▲ | $198.07M ▼ |
| Q3-2024 | $213.91M | $216.03M | $5.81M | $210.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.79M ▲ | $-12.2M ▲ | $14.94M ▲ | $19.11M ▲ | $21.85M ▲ | $-12.29M ▲ |
| Q2-2025 | $-16.04M ▼ | $-15.66M ▼ | $13.88M ▼ | $91K ▲ | $-1.69M ▼ | $-15.71M ▼ |
| Q1-2025 | $-15.99M ▼ | $-14.41M ▼ | $14.91M ▲ | $24K ▼ | $527K ▲ | $-14.46M ▼ |
| Q4-2024 | $-14.56M ▼ | $-10.2M ▼ | $-9.39M ▲ | $642K ▲ | $-18.95M ▲ | $-10.37M ▼ |
| Q3-2024 | $-10.27M | $-6.17M | $-30.18M | $13K | $-36.34M | $-6.25M |
CEO
Carmine N. Stengone MBA, MS
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 24
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:2.12M
Value:$24.95M
JOHNSON & JOHNSON
Shares:1.98M
Value:$23.28M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:1.72M
Value:$20.23M
Summary
Showing Top 3 of 65